Parkinson Hastalığı Demansı Tedavisi
Özet
Parkinson hastalığına (PH) bağlı demans, hastalığın sık görülen ve prognozu belirgin biçimde kötüleştiren önemli bir motor olmayan komplikasyonudur. Güncel bilgiler ışığında PH demansının etyopatogenezi; α-sinüklein agregasyonu, Alzheimer tipi eşlik eden patolojiler, kolinerjik ve monoaminerjik nörotransmitter eksiklikleri, sinaptik disfonksiyon, nöroinflamasyon ve mitokondriyal bozukluklar gibi çoklu mekanizmalara dayanmaktadır. Bu heterojen yapı, tedavi yaklaşımlarının da sınırlı ve semptomatik kalmasına neden olmaktadır. Farmakolojik tedavide en güçlü kanıt asetilkolinesteraz inhibitörleri için mevcuttur. Rivastigmin, PH demansı için onaylı tek ajan olup kognitif işlevlerde klinik olarak anlamlı iyileşmeler sağlamaktadır. Donepezil ve galantamin “muhtemelen faydalı” kabul edilmekle birlikte etkinlik ve tolerabilite verileri sınırlıdır. Memantin, iyi tolere edilmesine rağmen kognitif ve davranışsal semptomlar üzerindeki etkileri tutarsızdır ve araştırma aşamasında değerlendirilmektedir. Antiparkinsonian ilaçların kognitif etkileri heterojendir. Farmakolojik olmayan yaklaşımlarda egzersiz, kognitif rehabilitasyon ve nöromodülasyon yöntemleri potansiyel faydalar göstermiştir; ancak kanıt düzeyleri düşüktür. Güncel klinik ve preklinik çalışmalar; α-sinüklein hedefli immünoterapiler, lizozomal fonksiyon düzenleyiciler, nörotrofik ve sinaptik plastisiteyi artıran ajanlar üzerine yoğunlaşmaktadır. Multidisipliner ve bireyselleştirilmiş tedavi yaklaşımı önem taşımaktadır.
Referanslar
Degirmenci Y, Angelopoulou E, Georgakopoulou VE, Bougea A. Cognitive Impairment in Parkinson’s Disease: An Updated Overview Focusing on Emerging Pharmaceutical Treatment Approaches. Medicina. 01 Ekim 2023;59(10):1756.
Baiano C, Barone P, Trojano L, Santangelo G. Prevalence and Clinical Aspects of Mild Cognitive Impairment in Parkinson’s Disease: A Meta‐Analysis. Movement Disorders. Ocak 2020;35(1):45-54.
Gibson LL, Weintraub D, Lemmen R, Perera G, Chaudhuri KR, Svenningsson P, vd. Risk of Dementia in Parkinson’s Disease: A Systematic Review and Meta‐Analysis. Movement Disorders. Ekim 2024;39(10):1697-709.
Levy G, Tang MX, Louis ED, Côté LJ, Alfaro B, Mejia H, vd. The association of incident dementia with mortality in PD. Neurology. 10 Aralık 2002;59(11):1708-13.
Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of Psychiatric and Other Nonmotor Symptoms on Disability in Parkinson’s Disease. J American Geriatrics Society. Mayıs 2004;52(5):784-8.
Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson’s disease are important contributors to caregiver distress. Int J Geriatr Psychiatry. Ekim 1999;14(10):866-74.
Aarsland D, Andersen K, Larsen JP, Lolk A. Prevalence and Characteristics of Dementia in Parkinson Disease: An 8-Year Prospective Study. Arch Neurol. 01 Mart 2003;60(3):387.
Mayeux R. A Population-Based Investigation of Parkinson’s Disease With and Without Dementia: Relationship to Age and Gender. Arch Neurol. 01 Mayıs 1992;49(5):492.
Stern Y, Marder K, Tang MX, Mayeux R. Antecedent clinical features associated with dementia in Parkinson’s disease. Neurology. Eylül 1993;43(9):1690-1690.
Bakeberg MC, Gorecki AM, Kenna JE, Jefferson A, Byrnes M, Ghosh S, vd. Differential effects of sex on longitudinal patterns of cognitive decline in Parkinson’s disease. J Neurol. Mayıs 2021;268(5):1903-12.
Levy G, Schupf N, Tang M, Cote LJ, Louis ED, Mejia H, vd. Combined effect of age and severity on the risk of dementia in Parkinson’s disease. Annals of Neurology. Haziran 2002;51(6):722-9.
Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, vd. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers. 01 Temmuz 2021;7(1):47.
Alves G, Lange J, Blennow K, Zetterberg H, Andreasson U, Førland MG, vd. CSF Aβ42 predicts early-onset dementia in Parkinson disease. Neurology. 20 Mayıs 2014;82(20):1784-90.
Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, vd. Cognitive performance of GBA mutation carriers with early-onset PD: The CORE-PD study. Neurology. Mayıs 2012;78(18):1434-40.
Obi T, Nishioka K, Ross OA, Terada T, Yamazaki K, Sugiura A, vd. CLINICOPATHOLOGIC STUDY OF A SNCA GENE DUPLICATION PATIENT WITH PARKINSON DISEASE AND DEMENTIA. Neurology. 15 Ocak 2008;70(3):238-41.
Huang X, Chen P, Kaufer DI, Tröster AI, Poole C. Apolipoprotein E and Dementia in Parkinson Disease: A Meta-analysis. Arch Neurol. 01 Şubat 2006;63(2):189.
Williams-Gray CH, Goris A, Saiki M, Foltynie T, Compston DAS, Sawcer SJ, vd. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s Disease. J Neurol. Mart 2009;256(3):493-8.
Jasinska-Myga B, Opala G, Goetz CG, Tustanowski J, Ochudlo S, Gorzkowska A, vd. Apolipoprotein E Gene Polymorphism, Total Plasma Cholesterol Level, and Parkinson Disease Dementia. Arch Neurol. 01 Şubat 2007;64(2):261.
Grünewald A, Kasten M, Ziegler A, Klein C. Next-Generation Phenotyping Using the Parkin Example: Time to Catch Up With Genetics. JAMA Neurol. 01 Eylül 2013;70(9):1186.
Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, vd. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain. Kasım 2009;132(11):2958-69.
Wang Q, Liu J, Guo Y, Dong G, Zou W, Chen Z. Association between BDNF G196A (Val66Met) polymorphism and cognitive impairment in patients with Parkinson’s disease: a meta-analysis. Braz J Med Biol Res. 2019;52(8):e8443.
Lin CH, Fan JY, Lin HI, Chang CW, Wu YR. Catechol-O-methyltransferase (COMT) genetic variants are associated with cognitive decline in patients with Parkinson’s disease. Parkinsonism & Related Disorders. Mayıs 2018;50:48-53.
Periñán MT, Macías‐García D, Labrador‐Espinosa MÁ, Jesús S, Buiza‐Rueda D, Adarmes‐Gómez AD, vd. Association of PICALM with Cognitive Impairment in Parkinson’s Disease. Movement Disorders. Ocak 2021;36(1):118-23.
Kang SU, Park J, Ha S, Kim D, Pletnikova O, Redding-Ochoa J, vd. Dissecting the molecular landscape of Parkinson’s disease and Parkinson’s disease dementia using highly efficient snRNA-seq (HIF-snRNA-seq) [Internet]. Genomics; 2025 [a.yer 04 Haziran 2025]. Erişim adresi: http://biorxiv.org/lookup/doi/10.1101/2025.03.01.640894
Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson’s disease: A prospective, community‐based study. Annals of Neurology. Kasım 2005;58(5):773-6.
Sun C, Armstrong MJ. Treatment of Parkinson’s Disease with Cognitive Impairment: Current Approaches and Future Directions. Behavioral Sciences. 17 Nisan 2021;11(4):54.
Han J, Fan Y, Wu P, Huang Z, Li X, Zhao L, vd. Parkinson’s Disease Dementia: Synergistic Effects of Alpha-Synuclein, Tau, Beta-Amyloid, and Iron. Front Aging Neurosci. 11 Ekim 2021;13:743754.
Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, vd. Cognitive decline in Parkinson disease. Nat Rev Neurol. Nisan 2017;13(4):217-31.
Aarsland D, Taylor J, Weintraub D. Psychiatric issues in cognitive impairment. Movement Disorders. 15 Nisan 2014;29(5):651-62.
Reijnders JSAM, Ehrt U, Weber WEJ, Aarsland D, Leentjens AFG. A systematic review of prevalence studies of depression in Parkinson’s disease. Movement Disorders. 30 Ocak 2008;23(2):183-9.
Balaban H, Akbostancı MC. Hareket Bozukluklarında Kullanılan Ölçekler. Içinde: Elibol B, editör. Hareket Bozuklukları. Ankara: Rota Tıp Kitapevi; 2011. s. 511-27.
Pagonabarraga J, Kulisevsky J, Llebaria G, García‐Sánchez C, Pascual‐Sedano B, Gironell A. Parkinson’s disease‐cognitive rating scale: A new cognitive scale specific for Parkinson’s disease. Movement Disorders. 15 Mayıs 2008;23(7):998-1005.
Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, vd. The MoCA: Well-suited screen for cognitive impairment in Parkinson disease. Neurology. 09 Kasım 2010;75(19):1717-25.
Genç G, Ertan S. Parkinson Hastalığında Tedavi: Non-Motor Bulguların Yönetimi. Içinde: Çakmur R, İnce Günal D, editörler. Hareket Bozuklukları Tanı ve Tedavi Rehberi. 2. bs Ankara: Türk Nöroloji Derneği; 2023. s. 74-93.
Van Gerpen JA. Drug-Induced Parkinsonism: The Neurologist. Kasım 2002;8(6):363-70.
Christine CW, Aminoff MJ. Clinical differentiation of parkinsonian syndromes: Prognostic and therapeutic relevance. The American Journal of Medicine. Eylül 2004;117(6):412-9.
Rodnitzky RL. UpToDate. 2025. Cognitive impairment and dementia in Parkinson disease. Erişim adresi: https://www.uptodate.com/contents/cognitive-impairment-and-dementia-in-parkinson-disease?search=parkinson%20dementia&source=search_result&selectedTitle=1~74&usage_type=default&display_rank=1#H6
Gonzalez MC, Tovar‐Rios DA, Alves G, Dalen I, Williams‐Gray CH, Camacho M, vd. Cognitive and Motor Decline in Dementia with Lewy Bodies and Parkinson’s Disease Dementia. Movement Disord Clin Pract. Haziran 2023;10(6):980-6.
Değirmenci Y, Bora Tokçaer A. Atipik Parkinsonizmlerde Yaklaşım ve Tedavi İlkeleri. Içinde: Çakmur R, İnce Günal D, editörler. Hareket Bozuklukları Tanı ve Tedavi Rehberi. 2. bs Ankara: Türk Nöroloji Derneği; 2023. s. 94-107.
Portet F, Scarmeas N, Cosentino S, Helzner EP, Stern Y. Extrapyramidal Signs Before and After Diagnosis of Incident Alzheimer Disease in a Prospective Population Study. Arch Neurol [Internet]. 01 Eylül 2009 [a.yer 04 Haziran 2025];66(9). Erişim adresi: http://archneur.jamanetwork.com/article.aspx?doi=10.1001/archneurol.2009.196
Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology. 14 Kasım 2006;67(9):1605-11.
Smirnov DS, Galasko D, Edland SD, Filoteo JV, Hansen LA, Salmon DP. Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies. Neurology [Internet]. 19 Mayıs 2020 [a.yer 04 Haziran 2025];94(20). Erişim adresi: https://www.neurology.org/doi/10.1212/WNL.0000000000009434
Litvan I. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study. Brain. 01 Ocak 1997;120(1):65-74.
Litvan I, Mega MS, Cummings JL, Fairbanks L. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology. Kasım 1996;47(5):1184-9.
Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, vd. Criteria for the diagnosis of corticobasal degeneration. Neurology. 29 Ocak 2013;80(5):496-503.
Thanvi B. Vascular parkinsonism--an important cause of parkinsonism in older people. Age and Ageing. 11 Ocak 2005;34(2):114-9.
Dubois B, Pillon B. Cognitive deficits in Parkinson’s disease. J Neurol. 28 Kasım 1996;244(1):2-8.
Pooladgar P, Sakhabakhsh M, Taghva A, Soleiman-Meigooni S. Donepezil Beyond Alzheimer’s Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases. Iran J Pharm Res [İnternet]. 16 Ağustos 2022 [a.yer 04 Haziran 2025];21(1). Erişim adresi: https://brieflands.com/articles/ijpr-128408.html
Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 14 Mart 2012;2012(3):CD006504.
Nakano I, Hirano A. Parkinson’s disease: Neuron loss in the nucleus basalis without concomitant Alzheimer’s disease. Annals of Neurology. Mayıs 1984;15(5):415-8.
Mamikonyan E, Xie SX, Melvin E, Weintraub D. Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo‐controlled study. Movement Disorders. Haziran 2015;30(7):912-8.
Weintraub D, Hauser RA, Elm JJ, Pagan F, Davis MD, Choudhry A, vd. Rasagiline for mild cognitive impairment in Parkinson’s disease: A placebo‐controlled trial. Movement Disorders. Mayıs 2016;31(5):709-14.
Hanagasi HA, Gurvit H, Unsalan P, Horozoglu H, Tuncer N, Feyzioglu A, vd. The effects of rasagiline on cognitive deficits in Parkinson’s disease patients without dementia: A randomized, double‐blind, placebo‐controlled, multicenter study. Movement Disorders. 15 Ağustos 2011;26(10):1851-8.
Weintraub D, Mavandadi S, Mamikonyan E, Siderowf AD, Duda JE, Hurtig HI, vd. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 03 Ağustos 2010;75(5):448-55.
Marsh L, Biglan K, Gerstenhaber M, Williams JR. Atomoxetine for the treatment of executive dysfunction in Parkinson’s disease: A pilot open‐label study. Movement Disorders. 30 Ocak 2009;24(2):277-82.
Hinson VK, Delambo A, Elm J, Turner T. A Randomized Clinical Trial of Atomoxetine for Mild Cognitive Impairment in Parkinson’s Disease. Movement Disord Clin Pract. Mayıs 2017;4(3):416-23.
Ghosh A, Das S, Behera SK, Ramakrishnan K, Selvarajan S, Kandasamy P, vd. Atomoxetine Does Not Improve Complex Attention in Idiopathic Parkinson’s Disease Patients with Cognitive Deficits: A Meta-Analysis. Parkinson’s Disease. 18 Şubat 2020;2020:1-8.
Li Z, Wang P, Yu Z, Cong Y, Sun H, Zhang J, vd. The Effect of Creatine and Coenzyme Q10 Combination Therapy on Mild Cognitive Impairment in Parkinson’s Disease. Eur Neurol. 2015;73(3-4):205-11.
Da Silva FC, Iop RDR, De Oliveira LC, Boll AM, De Alvarenga JGS, Gutierres Filho PJB, vd. Effects of physical exercise programs on cognitive function in Parkinson’s disease patients: A systematic review of randomized controlled trials of the last 10 years. Ginsberg SD, editör. PLoS ONE. 27 Şubat 2018;13(2):e0193113.
Picelli A. Effects of treadmill training on cognitive and motor features of patients with mild to moderate Parkinson�s disease: a pilot, single-blind, randomized controlled trial. FN [İnternet]. 2016 [a.yer 04 Haziran 2025]; Erişim adresi: http://www.functionalneurology.com/common/php/portiere.php?ID=d5a11f0ff15217a5d1a64efc67173053
Silveira CRA, Roy EA, Intzandt BN, Almeida QJ. Aerobic exercise is more effective than goal-based exercise for the treatment of cognition in Parkinson’s disease. Brain and Cognition. Nisan 2018;122:1-8.
Song R, Grabowska W, Park M, Osypiuk K, Vergara-Diaz GP, Bonato P, vd. The impact of Tai Chi and Qigong mind-body exercises on motor and non-motor function and quality of life in Parkinson’s disease: A systematic review and meta-analysis. Parkinsonism & Related Disorders. Ağustos 2017;41:3-13.
McKee KE, Hackney ME. The Effects of Adapted Tango on Spatial Cognition and Disease Severity in Parkinson’s Disease. Journal of Motor Behavior. Kasım 2013;45(6):519-29.
Rios Romenets S, Anang J, Fereshtehnejad SM, Pelletier A, Postuma R. Tango for treatment of motor and non-motor manifestations in Parkinson’s disease: A randomized control study. Complementary Therapies in Medicine. Nisan 2015;23(2):175-84.
Baldassarre I, Rotondo R, Piccardi L, Leonardi L, Lanni D, Gaglione M, vd. The Effects of Multidisciplinary Intensive Rehabilitation on Cognitive and Executive Functions in Parkinson’s Disease: A Clinical Database Analysis. J Clin Med. 02 Temmuz 2024;13(13):3884.
Doruk D, Gray Z, Bravo GL, Pascual-Leone A, Fregni F. Effects of tDCS on executive function in Parkinson’s disease. Neuroscience Letters. Ekim 2014;582:27-31.
Del Felice A, Castiglia L, Formaggio E, Cattelan M, Scarpa B, Manganotti P, vd. Personalized transcranial alternating current stimulation (tACS) and physical therapy to treat motor and cognitive symptoms in Parkinson’s disease: A randomized cross-over trial. NeuroImage: Clinical. 2019;22:101768.
Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, vd. Update on treatments for nonmotor symptoms of Parkinson’s disease—an evidence‐based medicine review. Movement Disorders. Şubat 2019;34(2):180-98.
Wang HF, Yu JT, Tang SW, Jiang T, Tan CC, Meng XF, vd. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. Journal of Neurology, Neurosurgery & Psychiatry. 01 Şubat 2015;86(2):135-43.
Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment. The Lancet Neurology. Ağustos 2012;11(8):697-707.
Chitnis S, Rao J. Rivastigmine in Parkinson’s disease dementia. Expert Opinion on Drug Metabolism & Toxicology. Ağustos 2009;5(8):941-55.
Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, vd. Rivastigmine for Dementia Associated with Parkinson’s Disease. N Engl J Med. 09 Aralık 2004;351(24):2509-18.
Emre M, Poewe W, De Deyn PP, Barone P, Kulisevsky J, Pourcher E, vd. Long-term Safety of Rivastigmine in Parkinson Disease Dementia: An Open-Label, Randomized Study. Clinical Neuropharmacology. Ocak 2014;37(1):9-16.
Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, vd. Donepezil in Parkinson’s disease dementia: A randomized, double‐blind efficacy and safety study. Movement Disorders. Eylül 2012;27(10):1230-8.
Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, vd. Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int J Geriat Psychiatry. Ocak 2004;19(1):1-8.
Ravina B. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. Journal of Neurology, Neurosurgery & Psychiatry. 01 Temmuz 2005;76(7):934-9.
Y.Y. Szeto J, J.G. Lewis S. Current Treatment Options for Alzheimer’s Disease and Parkinson’s Disease Dementia. CN. 08 Nisan 2016;14(4):326-38.
Litvinenko IV, Odinak MM, Mogil’naya VI, Emelin AYu. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson’s disease (an open controlled trial). Neurosci Behav Physi. Kasım 2008;38(9):937-45.
Thomas AJ, Burn DJ, Rowan EN, Littlewood E, Newby J, Cousins D, vd. A comparison of the efficacy of donepezil in Parkinson’s disease with Dementia and Dementia with Lewy bodies. Int J Geriat Psychiatry. Ekim 2005;20(10):938-44.
Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A. Randomized controlled trial of memantine in dementia associated with Parkinson’s disease. Movement Disorders. 15 Haziran 2009;24(8):1217-21.
Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, vd. Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. AJP. 01 Ağustos 2015;172(8):731-42.
Wesnes KA, Aarsland D, Ballard C, Londos E. Memantine improves attention and episodic memory in Parkinson’s disease dementia and dementia with Lewy bodies. Int J Geriat Psychiatry. Ocak 2015;30(1):46-54.
Frost ED, Shi SX, Byroju VV, Pitton Rissardo J, Donlon J, Vigilante N, vd. Galantamine-Memantine Combination in the Treatment of Parkinson’s Disease Dementia. Brain Sciences. 21 Kasım 2024;14(12):1163.
Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Movement Disorders. 15 Kasım 2008;23(15):2248-50.
Molloy SA, Rowan EN, O’Brien JT, McKeith IG, Wesnes K, Burn DJ. Effect of levodopa on cognitive function in Parkinson’s disease with and without dementia and dementia with Lewy bodies. Journal of Neurology, Neurosurgery & Psychiatry. 25 Temmuz 2006;77(12):1323-8.
Iablonskaia AI, Fedorova NV, Bel’gusheva ME. [The effect of amantadine sulfate on cognitive disorders in patients with Parkinson’s disease]. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(7):24-30.
Fanciulli A, Assogna F, Caltagirone C, Spalletta G, Pontieri FE. Rotigotine for anxiety during wearing-off in Parkinson’s disease with dementia. Aging Clin Exp Res. Ekim 2013;25(5):601-3.
Portin R, Rinne UK. The effect of deprenyl (selegiline) on cognition and emotion in parkinsonian patients undergoing long-term levodopa treatment. Acta Neurologica Scandinavica. Temmuz 1983;68:135-44.
Frakey LL, Friedman JH. Cognitive Effects of Rasagiline in Mild-to-Moderate Stage Parkinson’s Disease Without Dementia. JNP. Ocak 2017;29(1):22-5.
Sano M, Stern Y, Marder K, Mayeux R. A controlled trial of piracetam in intellectually impaired patients with Parkinson’s disease. Movement Disorders. Ocak 1990;5(3):230-4.
Silveira CRA, MacKinley J, Coleman K, Li Z, Finger E, Bartha R, vd. Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. BMC Neurol. Aralık 2019;19(1):20.
Yang SY, Taanman JW, Gegg M, Schapira AHV. Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model. Human Molecular Genetics. 21 Temmuz 2022;31(14):2396-405.
Tai CH, Bellesi M, Chen AC, Lin CL, Li HH, Lin PJ, vd. A new avenue for treating neuronal diseases: Ceftriaxone, an old antibiotic demonstrating behavioral neuronal effects. Behavioural Brain Research. Mayıs 2019;364:149-56.
Hsieh MH, Meng WY, Liao WC, Weng JC, Li HH, Su HL, vd. Ceftriaxone reverses deficits of behavior and neurogenesis in an MPTP-induced rat model of Parkinson’s disease dementia. Brain Research Bulletin. Haziran 2017;132:129-38.
Pagan FL, Wilmarth B, Torres‐Yaghi Y, Hebron ML, Mulki S, Ferrante D, vd. Long‐Term Safety and Clinical Effects of Nilotinib in Parkinson’s Disease. Movement Disorders. Mart 2021;36(3):740-9.
Wu J, Xu X, Zheng L, Mo J, Jin X, Bao Y. Nilotinib inhibits microglia-mediated neuroinflammation to protect against dopaminergic neuronal death in Parkinson’s disease models. International Immunopharmacology. Ekim 2021;99:108025.
Pagan FernandoL, Hebron ML, Wilmarth B, Torres-Yaghi Y, Lawler A, Mundel EE, vd. Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial. JAMA Neurol. 01 Mart 2020;77(3):309.
Novak P, Pimentel Maldonado DA, Novak V. Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study. McKay JL, editör. PLoS ONE. 25 Nisan 2019;14(4):e0214364.
Svensson KA, Hao J, Bruns RF. Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disorders. Içinde: Advances in Pharmacology [Internet]. Elsevier; 2019 [a.yer 05 Haziran 2025]. s. 273-305. Erişim adresi: https://linkinghub.elsevier.com/retrieve/pii/S1054358919300249
Biglan K, Munsie L, Svensson KA, Ardayfio P, Pugh M, Sims J, vd. Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo‐Controlled Trial. Movement Disorders. Mart 2022;37(3):513-24.
Siddiqui T, Bhatt LK. Targeting Sigma-1 Receptor: A Promising Strategy in the Treatment of Parkinson’s Disease. Neurochem Res. Ekim 2023;48(10):2925-35.
Schenk DB, Koller M, Ness DK, Griffith SG, Grundman M, Zago W, vd. First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers: Immunotherapy for Parkinson’s Disease. Mov Disord. Şubat 2017;32(2):211-8.
Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, vd. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 01 Ekim 2018;75(10):1206.
Fernandez HH, Weintraub D, Macklin E, Litvan I, Schwarzschild MA, Eberling J, vd. Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial. Parkinsonism & Related Disorders. Eylül 2023;114:105511.
Hauser RA, Sutherland D, Madrid JA, Rol MA, Frucht S, Isaacson S, vd. Targeting neurons in the gastrointestinal tract to treat Parkinson’s disease. Clinical Parkinsonism & Related Disorders. 2019;1:2-7.
Barth AL, Schneider JS, Johnston TH, Hill MP, Brotchie JM, Moskal JR, vd. NYX‐458 Improves Cognitive Performance in a Primate Parkinson’s Disease Model. Movement Disorders. Nisan 2020;35(4):640-9.
Johnston JL, Reda SM, Setti SE, Taylor RW, Berthiaume AA, Walker WE, vd. Fosgonimeton, a Novel Positive Modulator of the HGF/MET System, Promotes Neurotrophic and Procognitive Effects in Models of Dementia. Neurotherapeutics. Mart 2023;20(2):431-51.
Huang R, Gao Y, Chen J, Duan Q, He P, Zhang J, vd. TGR5 Agonist INT-777 Alleviates Inflammatory Neurodegeneration in Parkinson’s Disease Mouse Model by Modulating Mitochondrial Dynamics in Microglia. Neuroscience. Mayıs 2022;490:100-19.
Holanda VAD, Didonet JJ, Costa MBB, Do Nascimento Rangel AH, Da Silva ED, Gavioli EC. Neuropeptide S Receptor as an Innovative Therapeutic Target for Parkinson Disease. Pharmaceuticals. 06 Ağustos 2021;14(8):775.
Neuropeptide-S affects cognitive impairment and depression-like behavior on MPTP induced experimental mouse model of Parkinson’s disease. Turk J Med Sci [İnternet]. 13 Aralık 2021 [a.yer 05 Haziran 2025];51(6). Erişim adresi: https://journals.tubitak.gov.tr/medical/vol51/iss6/40
Chang E, Wang J. Brain‐derived neurotrophic factor attenuates cognitive impairment and motor deficits in a mouse model of Parkinson’s disease. Brain and Behavior. Ağustos 2021;11(8):e2251.
Liu X, Wang C, Liu W, Song S, Fu J, Hayashi T, vd. Oral Administration of Silibinin Ameliorates Cognitive Deficits of Parkinson’s Disease Mouse Model by Restoring Mitochondrial Disorders in Hippocampus. Neurochem Res. Eylül 2021;46(9):2317-32.
Chu C, Yu L, Li Y, Guo H, Zhai Q, Chen W, vd. Meta-analysis of randomized controlled trials of the effects of probiotics in Parkinson’s disease. Food Funct. 24 Nisan 2023;14(8):3406-22.
Castelli V, d’Angelo M, Lombardi F, Alfonsetti M, Antonosante A, Catanesi M, vd. Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson’s disease models. Aging (Albany NY). 09 Mart 2020;12(5):4641-59.
Ishii T, Furuoka H, Kaya M, Kuhara T. Oral Administration of Probiotic Bifidobacterium breve Improves Facilitation of Hippocampal Memory Extinction via Restoration of Aberrant Higher Induction of Neuropsin in an MPTP-Induced Mouse Model of Parkinson’s Disease. Biomedicines. 08 Şubat 2021;9(2):167.
Park JS, Choe K, Lee HJ, Park TJ, Kim MO. Neuroprotective effects of osmotin in Parkinson’s disease-associated pathology via the AdipoR1/MAPK/AMPK/mTOR signaling pathways. J Biomed Sci. 11 Ağustos 2023;30(1):66.
Cheng C, Zhu X. Cordycepin mitigates MPTP-induced Parkinson’s disease through inhibiting TLR/NF-κB signaling pathway. Life Sci. 15 Nisan 2019;223:120-7.
Huang SY, Su ZY, Han YY, Liu L, Shang YJ, Mai ZF, vd. Cordycepin improved the cognitive function through regulating adenosine A2A receptors in MPTP induced Parkinson’s disease mice model. Phytomedicine. Şubat 2023;110:154649.
Guo X, Wu Y, Wang Q, Zhang J, Sheng X, Zheng L, vd. Huperzine A injection ameliorates motor and cognitive abnormalities via regulating multiple pathways in a murine model of Parkinson’s disease. Eur J Pharmacol. 05 Ekim 2023;956:175970.
Fang X, Ma J, Mu D, Li B, Lian B, Sun C. FGF21 Protects Dopaminergic Neurons in Parkinson’s Disease Models Via Repression of Neuroinflammation. Neurotox Res. Mart 2020;37(3):616-27.
Yang C, Wang W, Deng P, Wang X, Zhu L, Zhao L, vd. Fibroblast growth factor 21 ameliorates behavior deficits in Parkinson’s disease mouse model via modulating gut microbiota and metabolic homeostasis. CNS Neurosci Ther. Aralık 2023;29(12):3815-28.
Ding W, Lin H, Hong X, Ji D, Wu F. Poloxamer 188-mediated anti-inflammatory effect rescues cognitive deficits in paraquat and maneb-induced mouse model of Parkinson’s disease. Toxicology. 30 Nisan 2020;436:152437.
Zhang YL, Liu Y, Kang XP, Dou CY, Zhuo RG, Huang SQ, vd. Ginsenoside Rb1 confers neuroprotection via promotion of glutamate transporters in a mouse model of Parkinson’s disease. Neuropharmacology. 15 Mart 2018;131:223-37.
Qu S, Meng X, Liu Y, Zhang X, Zhang Y. Ginsenoside Rb1 prevents MPTP-induced changes in hippocampal memory via regulation of the α-synuclein/PSD-95 pathway. Aging (Albany NY). 04 Nisan 2019;11(7):1934-64.
Zhang X, Bai L, Zhang S, Zhou X, Li Y, Bai J. Trx-1 ameliorates learning and memory deficits in MPTP-induced Parkinson’s disease model in mice. Free Radic Biol Med. 20 Ağustos 2018;124:380-7.
Yang JS, Wu XH, Yu HG, Teng LS. Tangeretin inhibits neurodegeneration and attenuates inflammatory responses and behavioural deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson’s disease dementia in rats. Inflammopharmacology. Ağustos 2017;25(4):471-84.
Cummins L, Cates ME. Istradefylline: A novel agent in the treatment of “off” episodes associated with levodopa/carbidopa use in Parkinson disease. Ment Health Clin. Ocak 2022;12(1):32-6.
Ko WKD, Camus SM, Li Q, Yang J, McGuire S, Pioli EY, vd. An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models. Neuropharmacology. Kasım 2016;110(Pt A):48-58.
Savall ASP, Fidelis EM, de Mello JD, Quines CB, Denardin CC, Marques LS, vd. Neuroprotective effect of Eugenia uniflora against intranasal MPTP-induced memory impairments in rats: The involvement of pro-BDNF/p75NTR pathway. Life Sci. 01 Temmuz 2023;324:121711.
Petzinger GM, Fisher BE, McEwen S, Beeler JA, Walsh JP, Jakowec MW. Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson’s disease. Lancet Neurol. Temmuz 2013;12(7):716-26.
Tabak R, Aquije G, Fisher BE. Aerobic Exercise to Improve Executive Function in Parkinson Disease: A Case Series. Journal of Neurologic Physical Therapy. Haziran 2013;37(2):58-64.
Gratwicke J, Zrinzo L, Kahan J, Peters A, Beigi M, Akram H, vd. Bilateral Deep Brain Stimulation of the Nucleus Basalis of Meynert for Parkinson Disease Dementia: A Randomized Clinical Trial. JAMA Neurol. 01 Şubat 2018;75(2):169-78.
Pineda‐Pardo JA, Gasca‐Salas C, Fernández‐Rodríguez B, Rodríguez‐Rojas R, Del Álamo M, Obeso I, vd. Striatal Blood–Brain Barrier Opening in Parkinson’s Disease Dementia: A Pilot Exploratory Study. Movement Disorders. Ekim 2022;37(10):2057-65.
Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord. Mart 2000;15(2):201-11.
Borek LL, Friedman JH. Treating psychosis in people with Parkinson’s disease. Expert Opinion on Drug Safety. 04 Mayıs 2025;24(5):513-8.
Isaacson SH, Nasrallah H, Pahwa R, Alva G, Kremens D, Stahl SM. Management of Parkinson’s disease psychosis: first-line antipsychotic selection and rationale for continuing, combining, or switching. Expert Opinion on Pharmacotherapy. 13 Nisan 2025;26(6):707-17.
Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, vd. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Movement Disorders. Kasım 2006;21(11):1899-907.
Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series. Curr Med Res Opin. 2002;18(5):258-64.
Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, vd. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. The Lancet Neurology. Temmuz 2009;8(7):613-8.
